Skip to content
DataLookout
Menu

NCT07428993

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 25 words
    • Start date changed from estimate of Sep 2026 to Aug 21, 2026
    • Secondary endpoints: details revised at 2 of 3 entries
    • Site details revised
  2. Notable Start date: Jun 2026 to Sep 2026
    • Primary endpoint(s) modified
    • Secondary endpoints revised (3)
    • Study description revised
    v5
  3. Notable Recruitment opened
    • Site contact updated
    v4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  5. Notable Start date: Feb 2026 to Jun 2026v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Event-free survival (EFS), defined as time from SJCARB7H3-41BBL infusion to disease relapse, progressive disease, new systemic therapy, secondary malignancy or death
Timeframe: Time from SJCARB7H3-41BBL infusion to time of first event, followed up to 24-months post-infusion

Secondary (3)

Overall survival (OS), defined as time from SJCARB7H3-41BBL cell infusion to all-cause mortality.
Number of participants experiencing protocol-specified regimen-related toxicities.
Number of participants with successful manufacture of SJCARB7H3-41BBL cells of sufficient dose and planned product administration

Arms and interventions

3CAR4OS TreatmentExperimental

All patients will receive standard of care chemotherapy, which is not considered part of protocol therapy. Eligible patients will undergo apheresis prior to standard local control surgery for CAR T cell manufacture and then resume standard therapy. In the absence of progressive disease, eligible patients with available SJCARB7H3-41BBL product will receive lymphodepletion chemotherapy (fludarabine/cyclophosphamide) after the completion of standard chemotherapy, followed by SJCARB7H3-41BBL infusion. Pulmonary metastasectomy will be performed as indicated according to the standard of care and will be timed after (Regimen A) or before (Regimen B) lymphodepletion and SJCARB7H3-41BBL infusion. Following successful clearance of either regimen A or, if necessary, regimen B, the efficacy cohort will be initiated.

Drugs: Cyclophosphamide, Fludarabine, Mesna

Procedures: Apheresis, SJCARB7H3_41BBL infusion

Sites

1 site in 1 country

  • St. Jude Children's Research HospitalMemphis, Tennessee, United States